Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-14

Advancement to Part B of the trial was designed to be contingent upon the data from the Phase 1A clinical trial. These positive data were recently announced in heavily pretreated patients who received CHM 1101, on average, as 4th line therapy and demonstrated a 55% Disease Control Rate (DCR), ~10 months survival in patients who achieved disease control and with a manageable safety profile. One patient exceeded 18 months survival, two patients have exceeded 14 months survival and three patients remain alive and in follow up

The above is from today's announcement. To have achieved these results as a 4th line of treatment is incredible. Very few GBM patients remain healthy enough to have that chance, and the tumour wpuld be advanced.
To have 2nd line od treatment opens a far greater number of available patients, but also treats them at a much healthier time.
Lets see what results can be achieved. Credit to CHM for getting this underway so quickly.

$aud15 million market cap for potentially the first viable treatment for GBM is crazy. But then lokk at the rest of the pipeline! Its not very often these opportunities come around.